OP0253 WORLDWIDE TRENDS IN MORTALITY OF SYSTEMIC LUPUS ERYTHEMATOSUS BETWEEN 2000 AND 2015: ANALYSIS OF THE WORLD HEALTH ORGANIZATION DATABASE

Abstract

Background Although diagnosis, treatment and prevention strategies of Systemic Lupus Erythematosus (SLE) have further improved during the last two decades, the net benefit in term of global SLE-related mortality remains unknown. Objectives To describe the worldwide trends in SLE mortality between 2000 and 2015 using data of 125 countries from the World Health Organization (WHO) mortality database. To modelize SLE-related deaths taking into account temporal changes, geographical localization and country wealth. Methods We analyzed the WHO mortality database containing cause-specific mortality of participating countries. SLE-related deaths were identified using the international classification of disease 10 (ICD-10, code M32). In all countries which provided data between 2000 and 2015, sex-specific mortality rate was calculated for each year using the WHO reference population database. To have a better understanding of mortality fluctuations, countries were grouped geographically by continents and their nominal gross domestic product (GDP) per capita were retrieved from the United Nation database. A mixed regression model for repeated measures was used to take into account the time factor, GDP per capita and continent in SLE-related death. Results Between 2000 and 2015, a total of 97,008 SLE-related deaths occurred in 125 countries, which accounted for 0.021% of all deaths during the same period. World-wide, the overall mortality rate attributed to SLE remained stable (p=0.86) over the study years. However, we detected significant differences between continents (p=0.0006) with the mortality rate of Africa being significantly higher than that of Europe (p=0.004). There was a significant interaction between the continents and the study years (p=0.01) revealing a strong increase in the mortality rate attributed to SLE in Africa. We found a very strong association between SLE-attributed mortality and the GDP per capita (p Conclusion We observed drastic differences in the evolution of SLE-related mortality due to country geographic localization, wealth and ethnic factors. SLE-related remained stable as a whole but strongly increased in the African continent. Disclosure of Interests Marc SCHERLINGER: None declared, Jean Sibilia: None declared, Herve Devilliers: None declared, Laurent Arnaud Consultant for: Alexion, Amgen, AstraZeneca, GSK, Janssen-Cilag, LFB, Lilly, Menarini France, Novartis, Pfizer, Roche-Chugai, and UCB., Paid instructor for: Alexion, Amgen, AstraZeneca, GSK, Janssen-Cilag, LFB, Lilly, Menarini France, Novartis, Pfizer, Roche-Chugai, and UCB., Speakers bureau: Alexion, Amgen, AstraZeneca, GSK, Janssen-Cilag, LFB, Lilly, Menarini France, Novartis, Pfizer, Roche-Chugai, and UCB.